- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2013
- Public Summary Document (PSD) March 2013 PBAC Meeting - PDF
Adalimumab – March 2013
Adalimumab, injection, 40 mg in 0-8 mL pre-filled syringe, 40 mg in 0-8 mL pre-filled pen, Humira®
Last updated
8 November 2023